Peer-reviewed veterinary case report
Rush sublingual immunotherapy reduces itching in dogs with atopic
By Fujimura, M. & Ishimaru, H.·Published in Polish Journal of Veterinary Sciences·2016·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Rush sublingual immunotherapy in canine atopic dermatitis: a prospective pilot study
- Species:
- dog
Plain-English summary
A group of 20 dogs with itchy skin due to allergies (canine atopic dermatitis) were treated with a new method called rush sublingual immunotherapy (SLIT), which involved taking allergy extracts under the tongue. After 6 months of treatment, most dogs showed significant improvement in their symptoms, with a 38% reduction in the severity of their skin condition. Out of the 17 dogs that completed the trial, 13 had a noticeable improvement, while 2 showed only slight improvement, and 2 did not improve at all. Thankfully, there were no serious side effects reported during the study.
People also search for: dog itching treatment · sublingual immunotherapy for dogs · canine atopic dermatitis relief
Abstract
Abstract Twenty dogs with canine atopic dermatitis (CAD) were treated with rush sublingual immunotherapy (SLIT), with a 48 hour build-up phase and 6 months maintenance phase (treated by antigen once every 3-4 weeks). The canine atopic dermatitis extent and severity index (CADESI)-4 was evaluated before treatment (baseline) and after 6 months. An open, non-controlled, non-randomized pilot trial was conducted to assess the effectiveness and safety of rush SLIT for environmental allergen extracts (Dematophagoides pteronyssinus and D.farinae mix and other). Three dogs dropped out and 17 dogs finished the trial. CADESI-4 at baseline was 60.6±27.1 (range 17-107, n=17). After 6 months of SLIT treatment, CADESI-4 was 37.4±36.0 (range 5-152, n=17) (p <0.01), which was a 38.3% reduction. A significant improvement, defined as a CADESI-4 reduction of > 30%, was observed in 13 out of 17 dogs (76%). A moderate improvement, defined as a CADESI-4 reduction of ≦30%, was observed in 2 dogs (12%). In the other 2 dogs (12%), CADESI-4 worsened or showed no change. However, no severe adverse effects were observed during the trial. Therefore, rush SLIT against environmental allergen extract for CAD showed effectiveness and safety as evidenced by the reduction of CADESI-4 after 6 months SLIT without severe adverse effects.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1515/pjvs-2016-0001